PURPOSE: The recommended pharmacotherapy for secondary prevention of acute coronary syndrome (ACS) is long-term treatment with a combination of four therapeutic classes: beta-blockers, antiplatelet agents (including aspirin), statins or other lipid-lowering agents, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The aim of this study was to describe use and persistence of the recommended drug combination after the first occurrence of ACS in France. METHODS: This was a database cohort study of patients with first registration for ACS between 2004 and 2007 in a representative sample of the French healthcare insurance database (Echantillon Généraliste de Bénéficiaires, EGB). The drugs of interest were those recommended. Persistence was assessed for patients dispensed three or all four drug classes within 2 months following ACS. Discontinuation was defined by a gap of more than 6 weeks between two dispensations. The follow-up period was 24 months after ACS occurrence. RESULTS: Of 2,057 patients with incident ACS, 872 (42.4 %) had at least one dispensation of each of the four recommended drug classes, and 684 (33.3 %) had three of the four classes. Persistence to treatment at 24 months was 57.4 % (95 % CI [54.0-60.6]) for patients with four classes, and 55.5 % (95 % CI [51.6-59.1]) with three classes. Discontinuation of initial combination was higher in patients aged ≥ 65 years at ACS occurrence, those with associated ongoing chronic disease, and in those who did not suffer myocardial infarction. CONCLUSIONS: Post-ACS secondary prevention in France is not optimal, especially in patients who did not have myocardial infarction.
PURPOSE: The recommended pharmacotherapy for secondary prevention of acute coronary syndrome (ACS) is long-term treatment with a combination of four therapeutic classes: beta-blockers, antiplatelet agents (including aspirin), statins or other lipid-lowering agents, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The aim of this study was to describe use and persistence of the recommended drug combination after the first occurrence of ACS in France. METHODS: This was a database cohort study of patients with first registration for ACS between 2004 and 2007 in a representative sample of the French healthcare insurance database (Echantillon Généraliste de Bénéficiaires, EGB). The drugs of interest were those recommended. Persistence was assessed for patients dispensed three or all four drug classes within 2 months following ACS. Discontinuation was defined by a gap of more than 6 weeks between two dispensations. The follow-up period was 24 months after ACS occurrence. RESULTS: Of 2,057 patients with incident ACS, 872 (42.4 %) had at least one dispensation of each of the four recommended drug classes, and 684 (33.3 %) had three of the four classes. Persistence to treatment at 24 months was 57.4 % (95 % CI [54.0-60.6]) for patients with four classes, and 55.5 % (95 % CI [51.6-59.1]) with three classes. Discontinuation of initial combination was higher in patients aged ≥ 65 years at ACS occurrence, those with associated ongoing chronic disease, and in those who did not suffer myocardial infarction. CONCLUSIONS: Post-ACS secondary prevention in France is not optimal, especially in patients who did not have myocardial infarction.
Authors: Anne Lambert-Kerzner; Eric J Del Giacco; Ibrahim E Fahdi; Chris L Bryson; S Dee Melnyk; Hayden B Bosworth; Ryan Davis; Howard Mun; Jennifer Weaver; Casey Barnett; Tiffany Radcliff; Amanda Hubbard; Kevin D Bosket; Evan Carey; Allison Virchow; Renee Mihalko-Corbitt; Amy Kaufman; Kathy Marchant-Miros; P Michael Ho Journal: Circ Cardiovasc Qual Outcomes Date: 2012-07-01
Authors: Philippe Tuppin; Anke Neumann; Nicolas Danchin; Christine de Peretti; Alain Weill; Philippe Ricordeau; Hubert Allemand Journal: Arch Cardiovasc Dis Date: 2010-07-22 Impact factor: 2.340
Authors: Jacques Amar; Jean Ferrières; Jean-Pierre Cambou; Elisabeth Amelineau; Nicolas Danchin Journal: Arch Cardiovasc Dis Date: 2008-06-24 Impact factor: 2.340
Authors: P Blin; R Lassalle; C Dureau-Pournin; B Ambrosino; M A Bernard; A Abouelfath; H Gin; C Le Jeunne; A Pariente; C Droz; N Moore Journal: Diabetologia Date: 2012-01-06 Impact factor: 10.122
Authors: Mai Duong; Abdelilah Abouelfath; Regis Lassalle; Cécile Droz; Patrick Blin; Nicholas Moore Journal: Drug Saf Date: 2018-11 Impact factor: 5.606
Authors: Jeffrey L Birk; Robin Cumella; David Lopez-Veneros; Ammie Jurado; Emily K Romero; Amit Lazarov; Ian M Kronish Journal: Health Psychol Date: 2020-09 Impact factor: 4.267